About Be Bio
Be Bio is a company based in Cambridge (United States) founded in 2020. Be Bio has raised $356 million across 4 funding rounds from investors including Takeda Pharmaceuticals, RA Capital and Arch Venture Partners. Be Bio offers products and services including B Cell Medicines and Research Platform. Be Bio operates in a competitive market with competitors including Immusoft, JW Therapeutics, Walking Fish Therapeutics, Overland Pharmaceuticals and Cellective BioTherapy, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$356 M (USD)
in 4 rounds
-
Latest Funding Round
$92 M (USD), Series C
Jan 15, 2025
-
Investors
Takeda Pharmaceuticals
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Be Bio
Be Bio offers a comprehensive portfolio of products and services, including B Cell Medicines and Research Platform.
Engineered treatments for serious diseases like hemophilia B
Tools for advancing B cell therapies through publications
People of Be Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Be Bio
Be Bio has successfully raised a total of $356M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $92 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Be Bio
Be Bio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, RA Capital and Arch Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked |
Investor details for Be Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Be Bio
Investment portfolio details for Be Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Be Bio
Detailed financials for Be Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Be Bio Comparisons
Peer comparison for Be Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Be Bio
Be Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Immusoft, JW Therapeutics, Walking Fish Therapeutics, Overland Pharmaceuticals and Cellective BioTherapy, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
B cells are programmed as biofactories for therapeutic protein delivery.
|
|
| Locked | Locked | Locked |
Cell immunotherapy products are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Cell-based therapeutics for cancer and immunological disorders are developed.
|
|
| Locked | Locked | Locked |
-
|
|
| Locked | Locked | Locked |
B cell-based therapies are developed for autoimmunity, immunodeficiency, and cancers.
|
Detailed competitors of Be Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Be Bio
Complete news archive for Be Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Be Bio
Be Bio was founded in 2020.
Be Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Be Bio is a funded company, having raised a total of $356M across 4 funding rounds to date.
Be Bio was founded in 2020 in Cambridge, United States, and operates in the biotechnology sector. Proprietary autologous and allogeneic BeCM platforms are utilized to advance B cell therapies across oncology and rare diseases. Pipeline candidates are progressed in these areas, while the platform is extended to infectious diseases, neurological conditions, and autoimmune diseases.
Be Bio's top competitors include Immusoft, JW Therapeutics and Walking Fish Therapeutics.
Be Bio offers B Cell Medicines and Research Platform.
Be Bio has 8 investors. Key investors include Takeda Pharmaceuticals, RA Capital, Arch Venture Partners, Atlas Venture, and Bristol-Myers Squibb.